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1. Introduction 
High-grade glioma, such as anaplastic astrocitomas (AA, WHO grade 3) and glioblastomas 
multiforme (GBM, WHO grade 4) are extremely aggressive and highly infiltrative brain 
tumours (Kleihues & Cavenee, 2000; Louis et al., 2007). In most cases they recur locally after 
applying the standard multimodality treatment based on surgical resection, followed by 
radiotherapy and/or chemotherapy. Despite advances in medicine, malignant gliomas 
continue to carry a dismal prognosis, even though a modest increase (by 4.5 months) in 
median survival and quality of life has been achieved. The main limitation to the 
effectiveness of surgery and radiotherapy in patients suffering from high-grade glioma is 
that these techniques, based on the geometric definition of tumour volume, are not suitable 
to eradicate tumour infiltrating cells within normal brain tissue. Moreover adjuvant 
chemotherapy has little effect on prolonging survival in patients with GBM (Stupp et al., 
2005). As a consequence, novel therapeutic approaches, based on a better understanding of 
cancer biology, are needed. To this end, experimental therapies such as gene therapy 
(Mischel et al., 2003), antiangiogenic therapy (Van Meir et al., 2010), monoclonal antibodies 
(Zhu et al. 2010), cancer immunotherapy (Keunen et al., 2011), vaccines (Hickey et al., 2010), 
boron neutron capture therapy (BNCT) (Barth et al., 1992, 2005) and radioimmunotherapy 
(Joensuu, 2000) are under investigation. Among these, BNCT represents a promising 
adjuvant therapy for malignant glioma, and for other forms of cancer such as head/neck 
cancer. It is a binary form of radiation therapy based on the selective accumulation of 
boronated compounds within tumour cells which are then irradiated by low-energy thermal 
neutrons. The nuclear reaction that occurs between the stable isotope, 10B, and thermal 
neutrons, yields high-energy alpha particles and recoiling lithium nuclei which release most 
of their ionizing energy within a few microns (about one cell diameter), therefore limiting 
radiation damage only to 10B-containing cells. Thus, BNCT can be considered as a 
biologically targeted form of radiation therapy because of its ability to target tumour cells 
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through boron compounds which selectively accumulate within them. Given this selectivity 
of BNCT, infiltrating tumour cells, as well as subclinical lesions, can be targeted by 10B 
compounds and underwent the therapeutic effect.  
For effective BNCT a large amount of 10B nuclei (about 109 atoms of 10B per cell) (Barth & 
Soloway, 1997) should be selectively accumulated within tumour cells, whilst 10B 
concentration levels in blood and in normal brain tissues should be the lowest. At the same 
time, a tumour-to-brain (T:Br) 10B concentration ratio of at least 3:1 must be achieved to 
ensure the optimal therapeutic dose to the tumour. Furthermore a sufficient number of 
thermal neutrons (thermal neutron fluences should be greater than 1012 ncm-2) must be 
captured by 10B atoms into the target volume during irradiation (Barth & Soloway, 1997). 
BNCT therapy has been evaluated for safety and efficacy in several centres around the 
world. So far, no severe effects of BNCT-related toxicity have been observed (Phase I), 
whilst little evidence of therapeutic effectiveness has been evaluated (Phase II) in patients 
with GBM (Diaz, 2003). Presently the therapy is under experimentation in Phase II clinical 
trials, while a randomized Phase III study has not yet been justified because of previous 
disappointing results.  
Currently, the boron carrier most widely used for clinical purpose is the boronated 
derivative of the essential amino acid L-phenylalanine, p-boronophenylalanine (BPA). Due 
to its poor solubility at physiological pH, it is administrated as a complex with fructose 
(BPA-fr complex). It is widely accepted that BPA is actively transported across the blood 
brain barrier (BBB) into the normal glia, while its uptake within the tumour is due to an 
increased rate of L-amino acid transport across the tumour cell membrane (Wittig et al., 
2000). In addition, BPA accumulation within tumour cells increases during the cell cycle (S-
phase) so that its use in treating aggressive GBM might be an advantage. Furthermore it has 
been demonstrated that pre-treatment with L-tyrosine (Papaspyrou et al. 1994), or other 
molecules targeted by L or A amino acid transport systems, can enhance intracellular BPA 
accumulation (Wittig et al., 2000). Previous in vitro (Wittig et al., 2000) and in vivo (Capuani 
et al., 2008, 2009) studies have demonstrated that preloading with L-DOPA (a well-known 
molecule with chemical structure similar to those of L-tyrosine and BPA) improves the 
accumulation of BPA. As a consequence, more interest is being devoted to the potential 
clinical application of L-DOPA preloading. Indeed, due to the wide clinical experience with 
the administration of L-DOPA for the treatment of Parkinson’s disease, its use as a potential 
enhancer of BPA accumulation in BNCT clinical trials could be immediately applied. 
The main limitations for BNCT effectiveness are due to: a) insufficient 10B intake within 
tumour cells, even if the most efficient methods of 10B administration are utilised; b) the lack 
of reliable imaging methods for monitoring the bio-distribution of 10B-carriers in order to 
estimate both the effectiveness of the carrier and the optimal timing for neutron irradiation 
(that is when T:Br 10B concentration ratio achieves the maximum value whilst at the same 
time the 10B concentration in blood is the lowest).  
Our research work has focused on developing solutions to overcome these BNCT 
limitations, in order to make it a clinically useful treatment modality in the near future. 
Specifically, we have evaluated in vivo (using C6 glioma model) the pharmacokinetics of 
BPA, and the effect of L-DOPA preloading on BPA accumulation both in the tumour and 
normal tissues. Pharmacokinetic data were helpful in determining the optimal irradiation 
time, as well as to develop computational strategies in order to define as accurately as 
possible the radiation dose released within tumour and surrounding healthy tissues. 
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In order to determine the best fitting curve of BPA pharmacokinetics (used to extrapolate 
the BPA concentration over time after infusion), in vivo monitoring of 10B-carrier was 
performed using nuclear magnetic resonance (NMR), either by imaging (MRI) or by 
spectroscopy (MRS). In both cases, the fluorinated analogue of BPA, F-labelled BPA, was 
investigated using 19F-MRI and 19F-MRS (Porcari et al., 2006, 2008, 2009). All previously 
mentioned methodologies and strategies designed to overcome some fundamental 
limitations of BNCT therapy have been developed to ensure a straightforward transfer from 
pre-clinical to clinical applications. 
2. Principles of boron neutron capture therapy 
BNCT is an experimental, radio-therapeutic modality able to biologically target malignant 
cells. It theoretically allows a selective delivery of the radiation damage within an infiltrating 
cancer cell while preserving the surrounding healthy tissues.  
BNCT has been preferentially employed in clinical trials designed for the treatment of 
GBM (Henriksson et al., 2008; Yamamoto et al., 2008, 2011; van Rij et al., 2005). This high 
grade tumour of the central nervous system is highly malignant and extremely 
infiltrative, characterized by rapid tumour growth with a wide microscopic invasion of 
malignant cells within the normal parenchyma. It is extremely resistant to all current 
therapies, including surgery, chemotherapy, radiotherapy, immunotherapy and gene 
therapy. Despite advances in medicine, its prognosis is still very poor with a median 
survival time of less than one year (Ohgaki & Kleihues, 2005). Thus, GBM remains one of 
the challenges to be faced by physicians and scientists worldwide. BNCT holds 
therapeutic promise for these incurable tumours. Clinical interest in BNCT has also been 
focused on high-grade gliomas (Chanana et al., 1999), as well as the treatment of 
malignant meningiomas (Tamura et al., 2006) and cutaneous melanomas (Mishima & 
Kondoh, 2000). More recently, interest has been extended to other forms of neoplasms 
such as head-neck cancers (Kankaanranta et al., 2007), liver (Wittig et al., 2008a) and lung 
tumours (Suzuki et al., 2007), as well as undifferentiated thyroid cancers (Dagrosa et al., 
2007).  
The treatment is binary and is carried out following two distinct phases. Firstly, an 
intravenous infusion of 10B-enriched compounds is given to the patient, allowing the 
selective uptake of 10B-carriers within neoplastic cells. Subsequently, when the T:Br 10B 
concentration ratio has achieved its highest value (at least 3:1) and, at the same time, the 10B 
concentration in blood is the lowest, the patient is irradiated with low energy (E < 0.4eV, 
thermal) or higher energy (0.4eV ≤ E ≤ 10 keV, epithermal) neutrons. 
BNCT is based on the nuclear reaction 10B(n,)7Li (1) (Sauerwein, 1993) that occurs when 
the stable isotope, 10B (characterized by a high thermal neutron capture cross section) 
captures a thermal neutron (nth) to yield 11B* in an unstable form, which decays in highly 
cytotoxic alpha ( 4
2
H ) and lithium ( 7
3
Li ) particles (Fig. 1.a). Due to their high Linear 
Energy Transfer (LET) (ICRU, 1998), these heavy charged particles release along their 
paths (comparable with the cell diameter, 5-9 m) a great density of ionization 
responsible for elevated Relative Biological Effectiveness (RBE) (ICRU, 1998). Thus, the 
dose delivered and the radiation damage is mostly confined within the 10B-loaded 
tumour cell (Fig. 1.b). 
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Fig. 1. 10B(n,)7Li reaction (a); cellular damage of BNCT (b).  
The effectiveness of the therapy is dependent on two conditions: 
 a high number of 10B atoms must be selectively localized within neoplastic cells (at least 
20-35 μg/g ~109 atoms of 10B per targeted cell) (Barth et al., 1996; Barth & Soloway, 
1997); 
 a sufficient number of thermal neutrons has to reach and be captured by the 10B atoms 
into the target volume during irradiation (thermal neutron fluences should be greater 
than 1012 n·cm-2) (Barth et al., 1996; Barth & Soloway, 1997).  
Although theoretically only a few alpha particles, releasing their energy within a cancer cell, 
assure the cell death, both of the above conditions should be satisfied because of the low 
probability of interaction between a single 10B atom with a thermal neutron.  
The therapeutic gain of BNCT is strictly dependent on the achievable T:Br 10B concentration 
ratio between tumour and normal tissue. It has been established that the higher the T:Br 10B 
concentration ratio is, the better the therapeutic gain of BNCT. Moreover, the tolerance dose 
of normal tissues should not be exceeded. It is mainly dependent on the neutron capture 
reactions, 1H(n,γ)2H and 14N(n,p)14C (2) (Soloway et al., 1997), that occur when hydrogen, 
1H, and nitrogen, 14N, isotopes (with relative abundances of 3% and 10%, respectively, in 
normal tissue) capture thermal neutrons yielding low LET γ rays and high LET protons (2), 
respectively.  
 
1 2 1 2 2
th
14 14 14 15 14
th
H(n, ) H    H + n H H +γ(2.23MeV)
N(n,p) C  N + n N C + p(0.63MeV)
  
  
   
    
(2) 
Due to the small neutron capture cross-sections of 1H and 14N (σH = 0.332 and σN = 1.82 
barns; 1 barn = 10-24 cm2) compared with that of 10B (σB = 3838 barns), the dose released 
within surrounding healthy tissues is, in most of cases, much smaller than that delivered 
within the tumour, even though its value is dependent on neutron fluences. Thus, the upper 
limit of the neutron fluences is determined by the normal tissue tolerance dose for protons 
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and γ rays. As a consequence, for the best therapeutic result the T:Br 10B concentration ratio 
should be as high as possible. 
In order to satisfy the previous conditions, intensive investigations have been performed 
since the introduction of BNCT in most of the research centres worldwide. Considerable 
efforts have been directed towards the design and synthesis of new efficient boron agents, as 
well as in developing strategies to maximize the tumour boron uptake whilst minimizing, at 
the same time, 10B levels in blood and in normal brain. The disappointing outcomes of early 
BNCT clinical trials in the United States (Slatkin, 1991) were mainly due to the inability of 
thermal neutrons to deliver therapeutic neutron fluences to deep-sited brain tumours. To 
overcome this, the use of higher energy epithermal neutron beams was pursued because of 
their greater tissue penetrating properties. Indeed, when epithermal neutrons penetrate 
tissues, they are slowed down into the thermal neutron range (Seppälä et al., 2002, Coderre 
et al., 1997) by means of collisions with atoms (Fig. 2). Epithermal neutrons, therefore, allow 
delivery of therapeutic fluences of thermal neutrons at greater depths in the brain without 
reflecting the scalp or doing a craniotomy as required by using thermal fluences. 
 
0 1 2 3 4 5 6 7 8 9
Depth in Tissue (cm)
Thermal Beam
Epithermal Beam
T
h
e
r
m
a
l
N
e
u
tr
o
n
F
lu
x
10-1
100
101
T
h
e
r
m
a
l
N
e
u
tr
o
n
F
lu
x
 
Fig. 2. Variation of the thermal neutron fluence with tissue depth using a thermal or 
epithermal neutron beam (Coderre & Morris, 1999). 
Currently, nuclear reactors are the only sources of neutrons for clinical BNCT. The neutrons 
are produced by the fission process in the core of the reactor and are classified according 
their energy as thermal (Eth < 0.025eV), epithermal (0.4eV < Eepi < 10 keV) or fast (Efast > 10k 
eV). Since it is highly unlikely that the reactors can be sited in the main medical centres, 
alternative sources of thermal and epithermal neutrons for BNCT are being sought (Blue & 
Yanch, 2003). Among these, low-energy proton accelerators with low z targets are the most 
attractive. 
At present several reactors creating optimal epithermal neutron beams for BNCT are being 
used clinically worldwide. They include the Massachusetts Institute of Technology Reactor 
(MITR) (Busse et al., 2003) in the USA, the Kyoto University Research Reactor (KURR) and 
JRR4 at the Japan Atomic Energy Research Institute (Nakagawa, 2003) in Japan, and the RA-
6 CNEA reactor in Bariloche (Riley et al., 2008), Argentina. In Europe there are several 
clinical BNCT nuclear reactors: the FiR1 clinical reactor in Helsinki (Finland) (Joensuu et al., 
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2003), the LVR-15 reactor at the Nuclear Research Institute in Rez (Czech Republic) (Burian 
et al., 2004) and the clinical reactor at Studsvik Medical AB (Sweden) (Capala et al., 2003). 
2.1 Boron agents 
Since its inception, the development of boron delivery agents for BNCT therapy has been 
one of the most important topics to fulfil. For BNCT to be successful 10B carriers should 
satisfy the following requirements: 
 selectivity for malignant cells (with preferential 10B intracellular localization) compared 
with blood and contiguous normal tissue; 
 achievement of tumour boron concentrations of at least 20-35 μg10B/g (approximately 
109 boron atoms per cell); 
 permanence (at a constant concentration) within tumour during the BNCT radiation 
procedure and rapid clearance from both blood and normal tissues. This is necessary to 
estimate the radiation dose delivered to tumour, brain and vascular endothelium; 
 minimal systemic toxicity in order to achieve adequate tumour concentrations in vivo 
assuring, at the same time, favourable T:Br and tumour-to-blood (T:Bl) concentration 
ratios (at least 3:1); 
 So far, two 10B carriers have been used clinically: the polyhedral borane, sodium 
borocaptate (Na2B12H11SH or BSH) (Fig. 3), and the dihydroxyboryl derivate of 
phenylalanine, boronophenylalanine (C9H12BNO4 or BPA) (Fig. 3).  
Both compounds are characterized by low toxicities, selective tumour cell uptake, long 
tumour persistence and safety after their intravenous (i.v.) administration. 
 
 
Fig. 3. Chemical structures of BPA and BSH. 
Moreover, it has been demonstrated that either BPA or BSH may be able to target both 
proliferating and non-proliferating cells. This is of major importance for GBM treatment 
because of the relatively small percentage of GBM cells in the proliferative status at any time. 
Previously, BPA and BSH have been employed as boron agents in clinical trials designed for 
brain tumour treatments in the United States of America (Chanana et al.,1999; Coderre et 
al.,1999), in Europe (Phase I) (Capala et al., 2003; Joensuu et al., 2003, Burian et al., 1994) and 
in Japan (Phase II) (Nakagawa et al., 2003). The results of these trials confirmed the 
therapeutic efficacy of BNCT and provided the basis of the subsequent experimental clinical 
trials. However, the design of BNCT clinical protocols carried out using both mentioned 10B-
carriers was also influenced by the findings on animal model studies (Nakagawa et al., 2007; 
Smith et al., 1996).  
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In recent years, the clinical use of BPA for the GBM treatment has aroused great interest 
(Coderre et al., 1997; Capala et al., 2003; Joensuu et al., 2003) because of its encouraging 
results in experimental brain tumour therapy. Due to its low solubility in aqueous solutions 
at physiological conditions (pH ~ 7.4) it is administered as a complex with fructose (BPA–fr 
complex) (Yoshino et al., 1989). It was observed that BPA can be selectively accumulated 
either in the main tumour mass or in the microscopic cluster of tumour cell invading the 
normal parenchyma, even though the measured 10B concentration in the isolated cluster was 
only about 50% of that obtained in the main tumour mass (Smith et al., 1996). This result is 
of great importance for the efficacy of BNCT because the isolated clusters represent potential 
sites of tumour re-growth. Furthermore the ability of BPA to target the microscopic cluster 
within the normal brain suggests that it is actively transported through the BBB.  
Although the details of BPA accumulation into tumour cells are not completely understood, 
it is accepted that it is due to an elevated rate of amino acid transport across the tumour cell 
membrane (Wittig et al., 2000). Furthermore, there is evidence that BPA accumulation is 
enhanced by a pre-treatment with molecules vehiculated through L or A amino acid 
transport systems (Wittig et al., 2000). The increase of BPA intracellular accumulation was 
also demonstrated in mouse melanoma cells (Papaspyrou et al., 1994) using L-tyrosine pre-
administration. 
In addition, it has also been demonstrated that BPA accumulation within tumour cells 
increases during the cell cycle (S phase) (Nichols et al., 2002) so that its use in the treatment 
of aggressive brain gliomas might be an advantage. 
3. Main limitations for BNCT effectiveness 
BNCT is one of the most complex therapeutic modalities used to treat malignant brain 
tumours. Its success or failure is highly dependent on a combination of several chemical, 
physical and biological factors. Up to now, BNCT has been trialled to investigate its safety 
and efficacy in several centres worldwide. However, to date, the results of Phase I and II 
clinical trials have not shown therapeutic responses to justify Phase III trials.  
These disappointing results are mainly due to the following limitations. 
The first limitation was mostly due to insufficient uptake of 10B-labelled compound within 
tumour cells even though the most advanced methods of 10B administration were used 
(Chanana et al., 1999; Elowitz et al., 1998).  
Normally, the 10B uptake within brain tumours may be influenced by several factors such as 
the BBB permeability to the 10B-carrier, the plasma concentration profile of the 10B-agent 
(which is dependent on either the drug dose or the way of administration), the blood flow 
within tumour as well as the drug lipophilicity.  
So far, some strategies have been proposed to improve BNCT effectiveness by increasing 
BPA and BSH tumour intake. Some of these, including the use of pharmacological agents 
such as mannitol (Barth et al., 2000) or Cereport (RMP-7) (Yang et al., 1997) to disrupt the 
BBB, have been experimented on animal models (Barth et al., 2000; Yang et al., 1997). 
Although the results showed an increase in T:Br and T:Bl indices, the potential toxicities 
were not completely investigated. Moreover these methodologies have been classified as 
invasive, so numerous investigations are needed before considering them as potential 
applications in future clinical trials. 
The second main limitation for BNCT effectiveness was due to the lack of efficient imaging 
methods to monitor the spatial bio-distribution of 10B-labelled compounds and their 
www.intechopen.com
  
Management of CNS Tumors 
 
274 
pharmacokinetics, in order to estimate the efficacy of the carrier and the optimal timing of 
neutron irradiation. This ideal time is when the 10B concentration in tumour is higher than 
the concentration in blood and surrounding healthy tissues to prevent damage to these 
regions. Previous studies carried out in order to estimate brain-to-blood (Br:Bl), T:Br and 
T:Bl 10B concentration ratios using kinetic models (Ryynanen et al., 2000; 2002) and 
Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES) (Laakso et al., 2001) 
techniques, gave different results.  
Up to now several techniques (Wittig et al., 2008b) have been used to determine the spatial 
distribution and pharmacokinetics of 10B agents (Elowitz et al., 1998; Ryynanen et al 2000, 
2002, Laakso et al., 2001, Kabalka et al., 2003, Wang et al., 2004). Among these, MRI and MRS 
provide useful methods for non-invasive and non-destructive real-time monitoring of 10B 
compounds during BNCT treatment in vivo. Given the low sensitivity of the 10B NMR 
method (Bendel et al., 2001; Bendel 2005) and the intense proton background signal that 
makes 1H-MRS (Zuo et al., 1999) and Magnetic Resonance Spectroscopy Imaging (MRSI) 
(Bendel et al., 2005) techniques problematic in vivo, new strategies to detect BPA by NMR 
are in progress. 
4. Strategies to improve the efficacy of the therapy 
In order to make BNCT a clinical useful treatment modality in the near future, our work 
aims at investigating solutions to overcome the main limitations to the efficacy of the 
current methodology.  
Firstly, with the aim of improving the effectiveness of the therapy by increasing BPA 
tumour intake, the strategy used was to assess the effect of L-DOPA pre-loading on BPA 
accumulation within the tumour.  
L-DOPA is a well-known molecule with a chemical structure similar to those of L-tyrosine and 
BPA. Its use as a potential enhancer of BPA accumulation was suggested by previous 
encouraging results obtained on both mouse melanoma (Papaspyrou et al., 1994) and 9L rat 
gliosarcoma cells by pre-administration of L-tyrosine (Wittig et al., 2000). The enhancement of 
BPA accumulation in 9L rat gliosarcoma cells has been also replicated by using pre-treatment 
with both molecules targeted by L and A aminoacid transport system. These findings suggest 
that the substrate-coupled antiport (exchange) mechanism of these transporters is enhanced by 
the preloading of specific aminoacids. Previous in vitro (Wittig et al., 2000) and in vivo 
(Capuani et al., 2008; 2009) studies have demonstrated that L-DOPA preloading improves the 
accumulation of BPA in the tumour. Specifically it was demonstrated in vivo (Capuani et al., 
2008; 2009) that L-DOPA pre-administration on C6 glioma model gave rise to an increase of 
BPA tumour accumulation of 2.7 times with respect to those of controls. Conversely, no 
significant difference was evaluated by using the High Performance Liquid Chromatography 
(HPLC) method in both blood and normal brain between L-DOPA preloaded rats and 
controls. These findings are of fundamental importance for their impact on potential clinical 
applications. Indeed, the introduction of L-DOPA as a potential enhancer of BPA 
accumulation in BNCT clinical trials could be of immediate application because of its 
established clinical use as a treatment for Parkinson’s disease. 
Then, with the aim of investigating the pharmacokinetic behaviour of 10B carriers and their 
boron bio-distribution, both of them essential to evaluate the efficiency of the carrier and the 
optimal irradiation time, a novel approach to detect BPA was proposed. The strategy used was 
to map the fluorinated analogue of BPA (19F–BPA–fr complex) (Fig. 4) using 19F NMR in a way 
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similar to Positron Emission Tomography (PET) studies (Kabalka et al., 2003; Wang et al., 
2004). The feasibility of the method was previously demonstrated in vitro (Porcari et al., 2006).  
 
 
Fig. 4. Chemical structures of 19F–BPA and 19F–BPA–fr complex. 
Specifically, selective bio-distribution (Fig. 5.) (Porcari et al., 2008; 2009) of 19F–BPA–fr 
complex in C6 tumour-bearing rats as compared with normal brain has been demonstrated 
using 19F MRI. In addition, a better understanding of 19F–BPA pharmacokinetic was 
achieved because of the correlation between the results obtained by using both 19F MRI and 
19F MRS methodologies. Indeed the correlation between 19F MR monitoring on rat brain over 
4h after 19F–BPA–fr complex infusion and the quantification of 19F spectra collected from 
blood samples showed a maximum uptake of 19F–BPA in C6 glioma at 2.5h after infusion. 
Thus, 2.5h after infusion is the optimal time of neutron irradiation according to previous 
results (Hsieh et al., 2005) obtained by using PET measurements of 19F–BPA. 
These findings suggest the potential future application of 19F MRI and 19F MRS using 19F–
BPA in clinical trials. Indeed, the correlation of both techniques allows the mapping with the 
high spatial resolution characteristics of MRI of the distribution of 10B compounds and at the 
same time to follow the pharmacokinetic of 10B agents. Moreover, since 19F NMR can be 
performed using an 1H MR scanner by suitably tuning RF coils, only minor improvements 
in the MRI clinical scanner are required for future clinical applications. 
 
 
Fig. 5. 19F–BPA–fr complex bio-distribution map in C6 glioma model at 2.5h after infusion 
(Porcari et al., 2008) 
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5. Conclusion 
It is apparent from previous sections that BNCT is one of the most complex therapeutic 
modalities for brain tumour treatment. Due to the lack of progress in developing more 
effective treatments for high grade gliomas, the main challenge for BNCT in the near future, 
is to become a clinically useful treatment modality. Our work in optimizing the therapy has 
just this aim. Our research has been focused in overcoming some of the major limitations of 
BNCT effectiveness. 
Firstly, in order to improve 10B accumulation within the tumour, we demonstrated, both in 
vitro and in vivo, the potential of L-DOPA to enhance tumour uptake of BPA (Capuani et al., 
2008, 2009). The most interesting findings of this work were the increased BPA tumour 
uptake in vitro, with C6 glioma cells, as well as in vivo, with C6 glioma model. Indeed, the L-
DOPA preloading increased the BPA intracellular accumulation in C6 glioma cells 5 times 
with 4-hours of L-DOPA incubation (Capuani et al., 2008). The BPA tumour uptake in C6 
glioma model (Capuani et al., 2008) increased 2.7 times. Interestingly, there was no 
increasing of BPA uptake in a normal brain. These stimulating results encourage the 
potential use of L-DOPA in BNCT of brain tumours because of L-DOPA ability to induce a 
significant enhancement of BNCT effectiveness without remarkable associated side effects. 
Moreover, the use of L-DOPA in BNCT clinical trials could be also facilitated because of its 
long-standing clinical use as a treatment for Parkinson’s disease. 
In order to determine the optimal irradiation time improving the BNCT efficiency, 19F MR 
imaging and spectroscopy methodologies were proposed for investigating the 
pharmacokinetics and bio-distribution of BPA (Porcari et al., 2008; 2009). The correlation 
between both imaging and spectroscopic results obtained on glioma model highlights a 
better understanding of 19F–BPA uptake either in the tumour or in systemic circulation 
confirming evidence of maximum BPA uptake within the tumour at 2.5 hours after infusion 
(Porcari et al., 2008). These results demonstrate that both 19F MRI and 19F MRS are feasible 
and practical methodologies with potential future clinical application. Indeed, 19F NMR can 
be performed with an 1H MR clinical scanner with only minor hardware and software 
improvements. Both of the solutions proposed to improve BNCT effectiveness will help the 
therapy to overcome its main hindrances to become a clinically useful modality in the near 
future. 
6. Some standard abbreviations and symbols 
10B Boron-10 isotope 
BBB Blood Brain Barrier 
BNCT Boron Neutron Capture Therapy 
BPA p-boronophenylalanine 
BPA-fr complex 
p-boronophenylalanine-fructose 
complex 
Br:Bl brain-to-blood 
BSH sodium borocaptate 
14C Carbon-14 isotope 
γ rays gamma rays 
ICP-AES Inductively Coupled Plasma-Atomic 
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Emission Spectrometry 
19F-BPA fluorinated analogue of BPA 
19F-BPA-fr complex 19F-BPA-fructose complex 
19F-MRI Fluorine Magnetic Resonance Imaging 
19F-MRS 
Fluorine Magnetic Resonance 
Spectroscopy 
19F-NMR Fluorine Nuclear Magnetic Resonance 
GBM Glioblastomas Multiforme 
1H, 2H Hydrogen isotopes 
4
2
H  Alpha particle 
HPCL 
High Performance Liquid 
Chromatography 
7Li Lithium-7 isotope 
L-DOPA L-3,4-dihydroxyphenylalanine 
LET Linear Energy Transfer 
MRI Magnetic Resonance Imaging 
MRS Magnetic Resonance Spectroscopy 
MRSI 
Magnetic Resonance Spectroscopy 
Imaging 
nth thermal neutron 
14N, 15N Nitrogen isotopes  
NMR Nuclear Magnetic Resonance 
p proton 
PET Positron Emission Tomography 
σ cross-sections 
RBE Relative Biological Effectiveness 
T:Bl tumour-to-blood 
T:Br tumour-to-brain 
WHO World Health Organization 
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